Abstract Library

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Siebenhüner A

Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,

Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,

#1786 Targeted Therapies (TT) (Sunitinib and Everolimus) for Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). A Case Series

Introduction: Sunitinib (Sun) and Everolimus (Eve) are effective treatments for advanced GEP-NET. Lack of standard treatment sequencing and potential toxicities may preclude it´s use.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pérez de la Puente C

Authors: Pérez de la Puente C, Mando P, Rizzo M, Rivero S, Pesce V,

Keywords: TNE, therapy target,

#610 Effectiveness of PRRT for NETs in Germany: An Analysis of 450 Patients

Introduction: Peptide receptor radionuclide therapy targets somatostatin receptors expressed on well-differentiated neuroendocrine neoplasms. Retrospective monocentric studies indicate that peptide receptor radionuclide therapy is an effective treatment for patients with neuroendocrine neoplasms.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Hörsch D

Authors: Hörsch D, Ezziddin S, Haug A, Gratz K, Dunkelmann S,

Keywords: PRRT,

#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target

Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Kanakis G, Grimelius L, Trigidou R, Kaltsas G, Tsolakis A,

Keywords: somatostatin receptor subtypes, dopamine receptor 2, lung carcinoids,